Market Research Reports and Industry Reports

cAMP and cAMP Inhibited cGMP 3,5 Cyclic Phosphodiesterase 10A (Phosphodiesterase 10A1 or Phosphodiesterase 10A7 or PDE10A or EC 3.1.4.17 or EC 3.1.4.35) - Pipeline Review, H2 2017

  • DESCRIPTION
  • TABLE OF
    CONTENTS
  • RELATED
    REPORTS
  • SAMPLE REQUEST
  • REVIEWS
cAMP and cAMP Inhibited cGMP 3,5 Cyclic Phosphodiesterase 10A (Phosphodiesterase 10A1 or Phosphodiesterase 10A7 or PDE10A or EC 3.1.4.17 or EC 3.1.4.35) - Pipeline Review, H2 2017

Summary

cAMP and cAMP Inhibited cGMP 3,5 Cyclic Phosphodiesterase 10A (Phosphodiesterase 10A1 or Phosphodiesterase 10A7 or PDE10A or EC 3.1.4.17 or EC 3.1.4.35) pipeline Target constitutes close to 13 molecules. Out of which approximately 12 molecules are developed by companies and remaining by the universities/institutes. The latest report cAMP and cAMP Inhibited cGMP 3,5 Cyclic Phosphodiesterase 10A - Pipeline Review, H2 2017, outlays comprehensive information on the cAMP and cAMP Inhibited cGMP 3,5 Cyclic Phosphodiesterase 10A (Phosphodiesterase 10A1 or Phosphodiesterase 10A7 or PDE10A or EC 3.1.4.17 or EC 3.1.4.35) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.

cAMP and cAMP Inhibited cGMP 3,5 Cyclic Phosphodiesterase 10A (Phosphodiesterase 10A1 or Phosphodiesterase 10A7 or PDE10A or EC 3.1.4.17 or EC 3.1.4.35) - cAMP and cAMP-inhibited cGMP 3,5-cyclic phosphodiesterase 10A is an enzyme which plays a critical role in regulating cAMP and cGMP levels in the striatum. Many cellular responses are regulated by second messengers like cAMP and cGMP. PDE10A eliminate cAMP- and cGMP-mediated intracellular signaling by hydrolyzing the cyclic nucleotide to the corresponding nucleoside 5-prime monophosphate. The molecules developed by companies in Phase I and Preclinical stages are 1 and 11 respectively. Similarly, the universities portfolio in Preclinical stages comprises 1 molecules, respectively. Report covers products from therapy areas Central Nervous System and Oncology which include indications Schizophrenia, Huntington Disease, Lung Cancer, Psychiatric Disorders, Psychosis and Cognitive Disorders.

Furthermore, this report also reviews key players involved in cAMP and cAMP Inhibited cGMP 3,5 Cyclic Phosphodiesterase 10A (Phosphodiesterase 10A1 or Phosphodiesterase 10A7 or PDE10A or EC 3.1.4.17 or EC 3.1.4.35) targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape for cAMP and cAMP Inhibited cGMP 3,5 Cyclic Phosphodiesterase 10A (Phosphodiesterase 10A1 or Phosphodiesterase 10A7 or PDE10A or EC 3.1.4.17 or EC 3.1.4.35)
- The report reviews cAMP and cAMP Inhibited cGMP 3,5 Cyclic Phosphodiesterase 10A (Phosphodiesterase 10A1 or Phosphodiesterase 10A7 or PDE10A or EC 3.1.4.17 or EC 3.1.4.35) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in cAMP and cAMP Inhibited cGMP 3,5 Cyclic Phosphodiesterase 10A (Phosphodiesterase 10A1 or Phosphodiesterase 10A7 or PDE10A or EC 3.1.4.17 or EC 3.1.4.35) targeted therapeutics and enlists all their major and minor projects
- The report assesses cAMP and cAMP Inhibited cGMP 3,5 Cyclic Phosphodiesterase 10A (Phosphodiesterase 10A1 or Phosphodiesterase 10A7 or PDE10A or EC 3.1.4.17 or EC 3.1.4.35) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to cAMP and cAMP Inhibited cGMP 3,5 Cyclic Phosphodiesterase 10A (Phosphodiesterase 10A1 or Phosphodiesterase 10A7 or PDE10A or EC 3.1.4.17 or EC 3.1.4.35) targeted therapeutics

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for cAMP and cAMP Inhibited cGMP 3,5 Cyclic Phosphodiesterase 10A (Phosphodiesterase 10A1 or Phosphodiesterase 10A7 or PDE10A or EC 3.1.4.17 or EC 3.1.4.35)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and its most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding cAMP and cAMP Inhibited cGMP 3,5 Cyclic Phosphodiesterase 10A (Phosphodiesterase 10A1 or Phosphodiesterase 10A7 or PDE10A or EC 3.1.4.17 or EC 3.1.4.35) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope


List of Tables 4
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
cAMP and cAMP Inhibited cGMP 3,5 Cyclic Phosphodiesterase 10A (Phosphodiesterase 10A1 or Phosphodiesterase 10A7 or PDE10A or EC 3.1.4.17 or EC 3.1.4.35) - Overview 6
cAMP and cAMP Inhibited cGMP 3,5 Cyclic Phosphodiesterase 10A (Phosphodiesterase 10A1 or Phosphodiesterase 10A7 or PDE10A or EC 3.1.4.17 or EC 3.1.4.35) - Therapeutics Development 7
Products under Development by Stage of Development 7
Products under Development by Therapy Area 8
Products under Development by Indication 9
Products under Development by Companies 10
Products under Development by Universities/Institutes 12
cAMP and cAMP Inhibited cGMP 3,5 Cyclic Phosphodiesterase 10A (Phosphodiesterase 10A1 or Phosphodiesterase 10A7 or PDE10A or EC 3.1.4.17 or EC 3.1.4.35) - Therapeutics Assessment 14
Assessment by Mechanism of Action 14
Assessment by Route of Administration 15
Assessment by Molecule Type 16
cAMP and cAMP Inhibited cGMP 3,5 Cyclic Phosphodiesterase 10A (Phosphodiesterase 10A1 or Phosphodiesterase 10A7 or PDE10A or EC 3.1.4.17 or EC 3.1.4.35) - Companies Involved in Therapeutics Development 17
Astellas Pharma Inc 17
Celon Pharma SA 17
F. Hoffmann-La Roche Ltd 18
Glenmark Pharmaceuticals Ltd 18
Johnson & Johnson 19
Merck & Co Inc 19
Sunovion Pharmaceuticals Inc0
Takeda Pharmaceutical Co Ltd0
cAMP and cAMP Inhibited cGMP 3,5 Cyclic Phosphodiesterase 10A (Phosphodiesterase 10A1 or Phosphodiesterase 10A7 or PDE10A or EC 3.1.4.17 or EC 3.1.4.35) - Drug Profiles1
ADT-048 - Drug Profile1
Product Description1
Mechanism Of Action1
R&D Progress1
balipodect - Drug Profile2
Product Description2
Mechanism Of Action2
R&D Progress2
CPL-50003602 - Drug Profile5
Product Description5
Mechanism Of Action5
R&D Progress5
JNJ-42314415 - Drug Profile6
Product Description6
Mechanism Of Action6
R&D Progress6
MCI-020 - Drug Profile7
Product Description7
Mechanism Of Action7
R&D Progress7
PyP-1 - Drug Profile8
Product Description8
Mechanism Of Action8
R&D Progress8
RG-7203 - Drug Profile9
Product Description9
Mechanism Of Action9
R&D Progress9
RO-5461861 - Drug Profile 30
Product Description 30
Mechanism Of Action 30
R&D Progress 30
SEP-39 - Drug Profile 31
Product Description 31
Mechanism Of Action 31
R&D Progress 31
Small Molecule to Inhibit PDE10A for Schizophrenia - Drug Profile 32
Product Description 32
Mechanism Of Action 32
R&D Progress 32
Small Molecule to Inhibit PDE10A for Schizophrenia - Drug Profile 33
Product Description 33
Mechanism Of Action 33
R&D Progress 33
Small Molecules to Inhibit PDE10A for Schizophrenia and Psychosis - Drug Profile 34
Product Description 34
Mechanism Of Action 34
R&D Progress 34
THPP-1 - Drug Profile 35
Product Description 35
Mechanism Of Action 35
R&D Progress 35
cAMP and cAMP Inhibited cGMP 3,5 Cyclic Phosphodiesterase 10A (Phosphodiesterase 10A1 or Phosphodiesterase 10A7 or PDE10A or EC 3.1.4.17 or EC 3.1.4.35) - Dormant Products 36
cAMP and cAMP Inhibited cGMP 3,5 Cyclic Phosphodiesterase 10A (Phosphodiesterase 10A1 or Phosphodiesterase 10A7 or PDE10A or EC 3.1.4.17 or EC 3.1.4.35) - Discontinued Products 37
Appendix 38
Methodology 38
Coverage 38
Secondary Research 38
Primary Research 38
Expert Panel Validation 38
Contact Us 38
Disclaimer 39

List Of Tables

List of Tables
Number of Products under Development by Stage of Development, H2 2017 7
Number of Products under Development by Therapy Areas, H2 2017 8
Number of Products under Development by Indication, H2 2017 9
Number of Products under Development by Companies, H2 2017 10
Products under Development by Companies, H2 2017 11
Number of Products under Investigation by Universities/Institutes, H2 2017 12
Products under Investigation by Universities/Institutes, H2 2017 13
Number of Products by Stage and Mechanism of Actions, H2 2017 14
Number of Products by Stage and Route of Administration, H2 2017 15
Number of Products by Stage and Molecule Type, H2 2017 16
Pipeline by Astellas Pharma Inc, H2 2017 17
Pipeline by Celon Pharma SA, H2 2017 17
Pipeline by F. Hoffmann-La Roche Ltd, H2 2017 18
Pipeline by Glenmark Pharmaceuticals Ltd, H2 2017 18
Pipeline by Johnson & Johnson, H2 2017 19
Pipeline by Merck & Co Inc, H2 2017 20
Pipeline by Sunovion Pharmaceuticals Inc, H2 2017 20
Pipeline by Takeda Pharmaceutical Co Ltd, H2 2017 20
Dormant Projects, H2 2017 36
Discontinued Products, H2 2017 37

cAMP and cAMP Inhibited cGMP 3,5 Cyclic Phosphodiesterase 10A (Phosphodiesterase 10A1 or Phosphodiesterase 10A7 or PDE10A or EC 3.1.4.17 or EC 3.1.4.35) - Pipeline Review, H2 2017

cAMP and cAMP Inhibited cGMP 3,5 Cyclic Phosphodiesterase 10A (Phosphodiesterase 10A1 or Phosphodiesterase 10A7 or PDE10A or EC 3.1.4.17 or EC 3.1.4.35) - Pipeline Review, H2 2017cAMP and cAMP Inhibited

USD 3500View Report

Global Camping & Hiking Tents Sales Market Report 2017

In this report, the global Camping & Hiking Tents market is valued at USD XX million in 2016 and is expected to reach USD XX million by the end of

USD 4000View Report

DDD – Field Station Dinosaurs Museum And Camp Development – Kansas - Project Profile

Synopsis DDD Field Station Dinosaurs Museum And Camp Development Kansas - Project Profile contains information on the scope of the project including project overview and location. The profile also

USD 75View Report

RV (Recreational Vehicle) Parks And Campgrounds Market Global Report 2017

The global recreational vehicle parks and campgrounds market was estimated to be around $30 billion as of 2016. The global recreational vehicle parks and campgrounds made up around 66% of

USD 4000View Report

Fill The Form For Sample Request
Full Name :*
Bussiness Email: *
Email: *
Country :*
Contact No.*
Alternate No.
Note.:*Kindly provide us with your company id and get the sample reports at the earliest.
There is no Reviews available

Delivery Details

PDF FORMAT REPORTS will be delivered by email within 12 to 24 hours after placing the order (Mon-Fri IST)


+91 9987 2952 42

CHOOSE FORMAT

  • PDF    USD 3500
  • Site Licence    USD 7000
  • Enterprise Wide Licence    USD 10500
$ 3500

Reports Details

Published Date : Nov 2017
No. of Pages :39
Country :Global
Category :Pharmaceuticals and Healthcare
Publisher :
Report Delivery By :Email
Report Delivery Time :12 to 24 hours after placing the order.

Customized Research

If you do not find this specific report suitable to your exact needs then you can also opt for customized research report that will befit all your expectation. To specify your requirements CLICK HERE

 

We Accept

payment
  • fb
  • twitter
  • pinterest
  • linckedin
  • rss
  • youtube